Citizens JMP analyst Roy Buchanan raised the firm’s price target on Enanta (ENTA) to $24 from $23 and keeps an Outperform rating on the shares. Enanta remains on track to report Phase 2 results for oral RSV therapeutic candidate zelicapavir in Q3, but has indicated that further development of it and RSV-polymerase inhibitor EDP-323 will be dependent on a partner, the analyst tells investors in a research note. The firm has removed RSV from its valuation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA: